Of the patients with EGFR-mutated lung adenocarcinoma, 52.3% had no mutations in addition to the EGFR mutation, 33.9% had one concomitant mutation, and 10% had more than two concomitant mutations. Here, EGFR is linked to lung adenocarcinoma.